Indeed, we have confirmed that low-dose Hsp90 inhibitors effectually potentiate the effects of CRT on bladder cancer cells overexpressing erbB2 and NFκB in preclinical models [35]. The gene discussed is NFKB1; the disease is urinary bladder carcinoma.